-transparent.png){kind=logo}
Twenty-two patients with recurrent ovarian cancer were entered into a Phase II trial of edatrexate at a dose of 80 mg/m2 i.v. weekly for five consecutive weeks. One patient received an inadequate trial, and six did not complete one cycle due to adverse effects. There were 21 patients evaluable for toxicity and 15 for response. There were no objective responses, 10/15 (67%) had stable disease, 5/15 (33%) increasing disease. Toxicity was predominantly stomatitis and hematologic. Two patients developed skin rashes, and one experienced pulmonary toxicity felt to be related to the drug. Edatrexate administered in this dose and schedule has no demonstrated activity, but moderately severe toxicity in patients with previously treated advanced ovarian cancer.
E R Broun, and
K A Iseminger, and
M Bookman
August 1991,
American journal of clinical oncology,
E R Broun, and
K A Iseminger, and
M Bookman
February 1993,
American journal of clinical oncology,
E R Broun, and
K A Iseminger, and
M Bookman
June 1987,
Gynecologic oncology,
E R Broun, and
K A Iseminger, and
M Bookman
September 1987,
Gynecologic oncology,
E R Broun, and
K A Iseminger, and
M Bookman
January 2006,
Gynecologic oncology,
E R Broun, and
K A Iseminger, and
M Bookman
May 2002,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E R Broun, and
K A Iseminger, and
M Bookman
August 1992,
Gynecologic oncology,
E R Broun, and
K A Iseminger, and
M Bookman
January 2008,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
E R Broun, and
K A Iseminger, and
M Bookman
March 1986,
Cancer treatment reports,
E R Broun, and
K A Iseminger, and
M Bookman
February 2002,
American journal of clinical oncology,
